Imagine a rollercoaster that can get your body back in balance. That’s what researchers are discovering with Transcranial Electromagnetic Treatment (TEMT) for Alzheimer’s patients. In a pilot clinical trial, AD subjects who received daily TEMT for 2 months experienced a reversal of cognitive impairment. The treatment had immunologic effects on blood and cerebrospinal fluid (CSF) levels of cytokines, signaling molecules of the immune system. Subjects with lower baseline cytokine levels saw an increase after treatment, while those with higher levels experienced a decrease. This suggests that TEMT is capable of rebalancing cytokine levels in both the blood and brain. By affecting cytokine secretion from blood cells and brain cells, TEMT has the potential to prevent, stop, or even reverse the progression of Alzheimer’s disease. Excitingly, this may open up new avenues of treatment for other diseases of aging as well. To learn more about this groundbreaking research, check out the full article!

BackgroundThe immune system plays a critical role in the development and progression of Alzheimer’s disease (AD). However, there is disagreement as to whether development/progression of AD involves an over-activation or an under-activation of the immune system. In either scenario, the immune system’s cytokine levels are abnormal in AD and in need of rebalancing. We have recently published a pilot clinical trial (https://clinicaltrials.gov/ct2/show/NCT02958930) showing that 2 months of daily in-home Transcranial Electromagnetic Treatment (TEMT) was completely safe and resulted in reversal of AD cognitive impairment.MethodsFor the eight mild/moderate AD subjects in this published work, the present study sought to determine if their TEMT administration had immunologic effects on blood or CSF levels of 12 cytokines. Subjects were given daily in-home TEMT for 2 months by their caregivers, utilizing first-in-class MemorEM™ devices.ResultsFor eight plasma cytokines, AD subjects with lower baseline cytokine levels always showed increases in those cytokines after both a single treatment or after 2-months of daily TEMT. By contrast, those AD subjects with higher baseline cytokine levels in plasma showed treatment-induced decreases in plasma cytokines at both time points. Thus, a gravitation to reported normal plasma cytokine levels (i.e., a “rebalancing”) occurred with both acute and long-term TEMT. In the CSF, TEMT-induced a similar rebalancing for seven measurable cytokines, the direction and extent of changes in individual subjects also being linked to their baseline CSF levels.ConclusionOur results strongly suggest that daily TEMT to AD subjects for 2-months can “rebalance” levels for 11 of 12 cytokines in blood and/or brain, which is associated with reversal of their cognitive impairment. TEMT is likely to be providing these immunoregulatory effects by affecting cytokine secretion from: (1) blood cells traveling through the head’s vasculature, and (2) the brain’s microglia/astrocytes, choroid plexus, or neurons. This rebalancing of so many cytokines, and in both brain and systemic compartments, appears to be a remarkable new mechanism of TEMT action that may contribute substantially to it’s potential to prevent, stop, or reverse AD and other diseases of aging.

Read Full Article (External Site)